Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus CEFTAZIDIME IN DEXTROSE CONTAINER.
CEFIZOX IN PLASTIC CONTAINER vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to penicillin-binding proteins (PBPs) in bacterial cell wall, inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; severe infections: up to 2 g every 6-8 hours; maximum 12 g/day.
1-2 g intravenously every 8 hours.
None Documented
None Documented
1.5-2 hours; prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Primarily renal (80-90% unchanged), with biliary/fecal elimination being minor (<10%)
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic